# Pacira BioSciences, Inc.: financial statements, quarterly PCRX · Nasdaq · CIK 1396814 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pcrx.md) · [Financials](/companies/pcrx/financials.md) · [Filings](/companies/pcrx/filings.md) · [Insiders](/companies/pcrx/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pcrx/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [164](/filings/0001396814-24-000141.md) | [181 d](/filings/0001628280-26-012297.md) | [167](/filings/0001396814-25-000061.md) | [178](/filings/0001396814-25-000102.md) | [169](/filings/0001628280-25-050176.md) | [187 d](/filings/0001628280-26-012297.md) | [169](/filings/0001628280-26-028871.md) | [181](/filings/0001628280-26-052635.md) | [180](/filings/0001628280-25-050176.md) | [197 d](/filings/0001628280-26-012297.md) | [177](/filings/0001628280-26-028871.md) | [192](/filings/0001628280-26-052635.md) | | Cost of revenue | $m | [39.8](/filings/0001396814-24-000141.md) | [47.7 d](/filings/0001628280-26-012297.md) | [47.4](/filings/0001396814-25-000061.md) | [44.3](/filings/0001396814-25-000102.md) | [38.9](/filings/0001628280-25-050176.md) | [39.9 d](/filings/0001628280-26-012297.md) | [34.3](/filings/0001628280-26-028871.md) | [40.9](/filings/0001628280-26-052635.md) | [34.3](/filings/0001628280-25-050176.md) | [40.3 d](/filings/0001628280-26-012297.md) | [36.4](/filings/0001628280-26-028871.md) | [44.2](/filings/0001628280-26-052635.md) | | Research and development | $m | [20.8](/filings/0001396814-24-000141.md) | [19.5 d](/filings/0001628280-26-012297.md) | [18.2](/filings/0001396814-25-000061.md) | [20.3](/filings/0001396814-25-000102.md) | [19.1](/filings/0001628280-25-050176.md) | [23.9 d](/filings/0001628280-26-012297.md) | [25.3](/filings/0001628280-26-028871.md) | [28.2](/filings/0001628280-26-052635.md) | [26.0](/filings/0001628280-25-050176.md) | [37.5 d](/filings/0001628280-26-012297.md) | [28.1](/filings/0001628280-26-028871.md) | [30.2](/filings/0001628280-26-052635.md) | | Selling, general and administrative | $m | [67.9](/filings/0001396814-24-000141.md) | [65.8 d](/filings/0001628280-26-012297.md) | [72.0](/filings/0001396814-25-000061.md) | [68.1](/filings/0001396814-25-000102.md) | [74.3](/filings/0001628280-25-050176.md) | [79.6 d](/filings/0001628280-26-012297.md) | [86.8](/filings/0001628280-26-028871.md) | [88.6](/filings/0001628280-26-052635.md) | [91.8](/filings/0001628280-25-050176.md) | [102 d](/filings/0001628280-26-012297.md) | [93.9](/filings/0001628280-26-028871.md) | [91.8](/filings/0001628280-26-052635.md) | | Operating income | $m | [17.7](/filings/0001396814-24-000141.md) | [33.2 d](/filings/0001628280-26-012297.md) | [13.2](/filings/0001396814-25-000061.md) | [28.2](/filings/0001396814-25-000102.md) | [(140)](/filings/0001628280-25-050176.md) | [24.7 d](/filings/0001628280-26-012297.md) | [2.0](/filings/0001628280-26-028871.md) | [8.5](/filings/0001628280-26-052635.md) | [6.4](/filings/0001628280-25-050176.md) | [2.3 d](/filings/0001628280-26-012297.md) | [6.9](/filings/0001628280-26-028871.md) | [4.3](/filings/0001628280-26-052635.md) | | Interest expense | $m | [3.5](/filings/0001396814-23-000079.md) | [3.4 d](/filings/0001396814-24-000030.md) | [3.3](/filings/0001396814-24-000045.md) | [3.9](/filings/0001396814-25-000102.md) | [4.7](/filings/0001628280-25-050176.md) | [4.7 d](/filings/0001628280-26-012297.md) | [4.6](/filings/0001628280-26-028871.md) | [4.7](/filings/0001628280-26-052635.md) | [4.3](/filings/0001628280-25-050176.md) | [3.9 d](/filings/0001628280-26-012297.md) | [3.7](/filings/0001628280-26-028871.md) | [3.6](/filings/0001628280-26-052635.md) | | Income tax | $m | [5.7](/filings/0001396814-24-000141.md) | [8.9 d](/filings/0001628280-26-012297.md) | [4.7](/filings/0001396814-25-000061.md) | [17.7](/filings/0001396814-25-000102.md) | [4.6](/filings/0001628280-25-050176.md) | [9.5 d](/filings/0001628280-26-012297.md) | [3.9](/filings/0001628280-26-028871.md) | [2.9](/filings/0001628280-26-052635.md) | [4.1](/filings/0001628280-25-050176.md) | [(1.1) d](/filings/0001628280-26-012297.md) | [2.1](/filings/0001628280-26-028871.md) | [(2.1)](/filings/0001628280-26-052635.md) | | Net income | $m | [10.9](/filings/0001396814-24-000141.md) | [24.9 d](/filings/0001628280-26-012297.md) | [9.0](/filings/0001396814-25-000061.md) | [18.9](/filings/0001396814-25-000102.md) | [(143)](/filings/0001628280-25-050176.md) | [16.0 d](/filings/0001628280-26-012297.md) | [4.8](/filings/0001628280-26-028871.md) | [(4.8)](/filings/0001628280-26-052635.md) | [5.4](/filings/0001628280-25-050176.md) | [1.6 d](/filings/0001628280-26-012297.md) | [2.9](/filings/0001628280-26-028871.md) | [4.7](/filings/0001628280-26-052635.md) | | Diluted EPS | $ per share | [0.23](/filings/0001396814-24-000141.md) | not reported | [0.19](/filings/0001396814-25-000061.md) | [0.39](/filings/0001396814-25-000102.md) | [(3.11)](/filings/0001628280-25-050176.md) | not reported | [0.10](/filings/0001628280-26-028871.md) | [(0.11)](/filings/0001628280-26-052635.md) | [0.12](/filings/0001628280-25-050176.md) | not reported | [0.07](/filings/0001628280-26-028871.md) | [0.12](/filings/0001628280-26-052635.md) | | Basic EPS | $ per share | [0.23](/filings/0001396814-24-000141.md) | not reported | [0.19](/filings/0001396814-25-000061.md) | [0.41](/filings/0001396814-25-000102.md) | [(3.11)](/filings/0001628280-25-050176.md) | not reported | [0.10](/filings/0001628280-26-028871.md) | [(0.11)](/filings/0001628280-26-052635.md) | [0.12](/filings/0001628280-25-050176.md) | not reported | [0.07](/filings/0001628280-26-028871.md) | [0.12](/filings/0001628280-26-052635.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [99.1](/filings/0001396814-23-000079.md) | [153](/filings/0001396814-25-000041.md) | [184](/filings/0001396814-24-000045.md) | [247](/filings/0001396814-24-000098.md) | [246](/filings/0001396814-24-000141.md) | [277](/filings/0001628280-26-012297.md) | [284](/filings/0001396814-25-000061.md) | [300](/filings/0001396814-25-000102.md) | [148](/filings/0001628280-25-050176.md) | [159](/filings/0001628280-26-052635.md) | [144](/filings/0001628280-26-028871.md) | [206](/filings/0001628280-26-052635.md) | | Current assets | $m | [447](/filings/0001396814-23-000079.md) | [510](/filings/0001396814-25-000041.md) | [543](/filings/0001396814-24-000045.md) | [632](/filings/0001396814-24-000098.md) | [690](/filings/0001396814-24-000141.md) | [745](/filings/0001628280-26-012297.md) | [760](/filings/0001396814-25-000061.md) | [746](/filings/0001396814-25-000102.md) | [563](/filings/0001628280-25-050176.md) | [548](/filings/0001628280-26-052635.md) | [515](/filings/0001628280-26-028871.md) | [615](/filings/0001628280-26-052635.md) | | Total assets | $m | [1,534](/filings/0001396814-23-000079.md) | [1,574](/filings/0001396814-25-000041.md) | [1,583](/filings/0001396814-24-000045.md) | [1,647](/filings/0001396814-24-000098.md) | [1,522](/filings/0001396814-24-000141.md) | [1,554](/filings/0001628280-26-012297.md) | [1,587](/filings/0001396814-25-000061.md) | [1,537](/filings/0001396814-25-000102.md) | [1,298](/filings/0001628280-25-050176.md) | [1,265](/filings/0001628280-26-052635.md) | [1,209](/filings/0001628280-26-028871.md) | [1,244](/filings/0001628280-26-052635.md) | | Current liabilities | $m | [93.7](/filings/0001396814-23-000079.md) | [97.4](/filings/0001396814-25-000041.md) | [93.4](/filings/0001396814-24-000045.md) | [92.7](/filings/0001396814-24-000098.md) | [306](/filings/0001396814-24-000141.md) | [310](/filings/0001628280-26-012297.md) | [315](/filings/0001396814-25-000061.md) | [313](/filings/0001396814-25-000102.md) | [107](/filings/0001628280-25-050176.md) | [121](/filings/0001628280-26-052635.md) | [109](/filings/0001628280-26-028871.md) | [122](/filings/0001628280-26-052635.md) | | Total liabilities | $m | [703](/filings/0001396814-23-000079.md) | [704](/filings/0001396814-25-000041.md) | [691](/filings/0001396814-24-000045.md) | [768](/filings/0001396814-24-000098.md) | [772](/filings/0001396814-24-000141.md) | [775](/filings/0001628280-26-012297.md) | [788](/filings/0001396814-25-000061.md) | [779](/filings/0001396814-25-000102.md) | [570](/filings/0001628280-25-050176.md) | [572](/filings/0001628280-26-052635.md) | [555](/filings/0001628280-26-028871.md) | [572](/filings/0001628280-26-052635.md) | | Long-term debt | $m | not reported | [522](/filings/0001396814-25-000041.md) | not reported | not reported | not reported | [384](/filings/0001628280-26-012297.md) | [583](/filings/0001396814-25-000061.md) | [580](/filings/0001396814-25-000102.md) | [377](/filings/0001628280-25-050176.md) | [372](/filings/0001628280-26-052635.md) | [368](/filings/0001628280-26-028871.md) | [363](/filings/0001628280-26-052635.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [202](/filings/0001628280-26-012297.md) | not reported | not reported | [0.0](/filings/0001628280-25-050176.md) | [0.0](/filings/0001628280-26-012297.md) | not reported | not reported | | Shareholders' equity | $m | [832](/filings/0001396814-24-000141.md) | [870](/filings/0001628280-26-012297.md) | [892](/filings/0001396814-25-000102.md) | [879](/filings/0001628280-25-050176.md) | [750](/filings/0001628280-25-050176.md) | [778](/filings/0001628280-26-052635.md) | [799](/filings/0001628280-26-052635.md) | [758](/filings/0001628280-26-052635.md) | [727](/filings/0001628280-25-050176.md) | [693](/filings/0001628280-26-052635.md) | [654](/filings/0001628280-26-052635.md) | [672](/filings/0001628280-26-052635.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [44.4 d](/filings/0001396814-24-000141.md) | [47.6 d](/filings/0001628280-26-012297.md) | [49.1](/filings/0001396814-25-000061.md) | [53.2 d](/filings/0001396814-25-000102.md) | [53.9 d](/filings/0001628280-25-050176.md) | [33.1 d](/filings/0001628280-26-012297.md) | [35.5](/filings/0001628280-26-028871.md) | [12.0 d](/filings/0001628280-26-052635.md) | [60.8 d](/filings/0001628280-25-050176.md) | [43.7 d](/filings/0001628280-26-012297.md) | [25.7](/filings/0001628280-26-028871.md) | [57.5 d](/filings/0001628280-26-052635.md) | | Capital expenditure | $m | [3.4 d](/filings/0001396814-24-000141.md) | [1.8 d](/filings/0001628280-26-012297.md) | [2.8](/filings/0001396814-25-000061.md) | [1.6 d](/filings/0001396814-25-000102.md) | [4.1 d](/filings/0001628280-25-050176.md) | [2.1 d](/filings/0001628280-26-012297.md) | [8.5](/filings/0001628280-26-028871.md) | [2.7 d](/filings/0001628280-26-052635.md) | [3.9 d](/filings/0001628280-25-050176.md) | [0.2 d](/filings/0001628280-26-012297.md) | [2.7](/filings/0001628280-26-028871.md) | [1.3 d](/filings/0001628280-26-052635.md) | | Share repurchases | $m | [0.0 d](/filings/0001396814-24-000141.md) | [0.0 d](/filings/0001628280-26-012297.md) | not reported | not reported | [0.0 d](/filings/0001628280-25-050176.md) | [0.0 d](/filings/0001628280-26-012297.md) | [0.0](/filings/0001628280-26-028871.md) | [50.0 d](/filings/0001628280-26-052635.md) | [50.0 d](/filings/0001628280-25-050176.md) | [48.2 d](/filings/0001628280-26-012297.md) | [50.0](/filings/0001628280-26-028871.md) | [0.0 d](/filings/0001628280-26-052635.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [45.8](/filings/0001396814-23-000079.md) | [45.9](/filings/0001396814-24-000045.md) | [52.1](/filings/0001396814-24-000098.md) | [52.1](/filings/0001396814-24-000141.md) | [52.2](/filings/0001396814-25-000061.md) | [50.5](/filings/0001396814-25-000102.md) | [46.1](/filings/0001628280-25-050176.md) | [46.5](/filings/0001628280-26-028871.md) | [45.5](/filings/0001628280-26-052635.md) | [44.5](/filings/0001628280-25-050176.md) | [40.9](/filings/0001628280-26-028871.md) | [40.3](/filings/0001628280-26-052635.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 39,861,886 at 2026-08-03, from the cover of the [10-Q filed 2026-08-04](/filings/0001628280-26-052635.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.